INTRODUCTION
In mammals, the innate immune system is the first line of host defense. The system is an evolutionarily, conserved form of microbial defense, as indicated by shared pathogen recognition, signaling pathways, and functional mechanisms between mammals and Drosophila (reviewed in refs. [1, 2] ). Bactericidal/permeability-increasing protein (BPI) is a component of the innate defense, and binding of BPI to Gram-negative bacteria causes an increase in outer membrane permeability and eventually, inner membrane damage followed by cell death [3, 4] . An evolutionarily conservation of BPI is indicated by the presence of BPI orthologs in several species, ranging from mouse to rainbow trout [5, 6] . BPI consists of an aminoterminal domain important for high-affinity binding to the lipid A moiety of lipopolysaccharide (LPS) of Gram-negative bacteria and a carboxy-terminal domain mediating opsonization [7] [8] [9] . Consistent with its high affinity for LPS, BPI is a paralogue to the acute-phase LPS-binding protein (LBP; reviewed in ref. [10] ). LBP is a 60-kDa glycoprotein that binds LPS and delivers it to membrane-bound CD14/Toll-like receptor 4 (TLR-4) on inflammatory cells, thus evoking a strong, inflammatory response with increased secretion of proinflammatory cytokines, e.g., tumor necrosis factor ␣ (TNF-␣) and interleukin 1 (IL-1; reviewed in ref. [11] ). In addition to the involvement of LBP, a LPS-MD2 complex was identified recently as a potent trigger of TLR-4 activation [12] . When secreted excessively, TNF-␣ and IL-1 may give rise to septic shock with multiorgan failure (reviewed in ref. [13] ). Thus, septic shock can be viewed as an uncontrolled and exaggerated inflammatory response, although recent results indicate that sepsis in later stages may be characterized by a severely compromised immune system (reviewed in ref. [14] ). BPI counteracts the LPS-initiated inflammatory response by binding and neutralizing LPS [15] . Therefore, BPI is of potential use in treatment of sepsis caused by Gram-negative infections and other situations where LPS plays a role [16, 17] .
The neutrophil granulocyte is the major effector cell in the human innate defense against invading microbes. Neutrophils store potent, microbicidal proteins and peptides in different granules. Several antimicrobial proteins, such as myeloperoxidase (MPO), serine proteases, defensins, and BPI, dominate the content of the azurophil granules (reviewed in refs. [18, 19] ). BPI is a major constituent in neutrophils [20, 21] but is also present in granules of human eosinophils [22] and on the surface of monocytes [23] . Moreover, certain epithelial cells can be induced to synthesize BPI [24] , and BPI-mRNA is also present in the testis [5] .
The content of the different granule subtypes of the neutrophil is determined by the synthesis of proteins belonging to different granule subtypes separated in time during maturation [19] . Azurophil granule proteins are the first to be expressed during the promyelocyte (PM) stage, followed by specific granule proteins in myelocytes (MC). Accordingly, transcription of BPI is regulated positively by acute myeloid leukemia 1 and PU.1 [25] , factors also involved in transcription of other azurophil granule proteins. Several independent observations indicate, however, that transcriptional regulation of BPI is distinct from that of other azurophil granule proteins; newborn children are specifically deficient in BPI and are still equipped with normal amounts of other azurophil granule proteins, such as MPO and defensins [26, 27] , arguing for a distinct regulation of BPI expression. Moreover, in cases of specific granule deficiency (SGD), a rare disease with absent gene expression of several proteins stored in specific granules, BPI is also affected [28] . This disease has been linked to homozygous elimination of the neutrophil transcription factor CCAAT/enhancer-binding protein (C/EBP)ε [28, 29] , suggesting that C/EBPε is involved in the regulation of BPI, and most other azurophil granule proteins are regulated by C/EBP␣ [30, 31] . The human PM cell line NB4 does not express detectable amounts of BPI. Treatment of the cells with all-trans retinoic acid (ATRA) results in induction of neutrophil maturation, including upregulation of C/EBP␤ and C/EBPε [32, 33] . One of the questions we asked was whether this induced differentiation includes up-regulation of BPI expression and whether it affects the binding of C/EBPs to the BPI promoter.
We now report that in vivo, BPI mRNA is expressed in MC and metamyelocytes (MM), cells also showing expression of mRNAs for specific granule proteins. ATRA strongly induces BPI expression in human myeloid NB4 cells by mechanisms dependent on de novo protein synthesis. Moreover, ATRAinduced expression correlates to binding of C/EBP␤ and C/EBPε to the proximal promoter of BPI. We conclude that binding of C/EBP␤ and C/EBPε, but not of C/EBP␣, to the BPI promoter distinguishes BPI from other investigated azurophil granule proteins and provides an explanation for the expression pattern of BPI during neutropoiesis.
MATERIALS AND METHODS

Cell culture
Human PM NB4 cells [34] were maintained in RPMI 1640 with 10% fetal calf serum (PAA Laboratories GmbH, Pasching, Austria). In induction experiments, ATRA (Sigma-Aldrich, St. Louis, MO) was added to a final concentration of 10 M for the incubation times indicated. For inhibition of protein synthesis, cycloheximide (Sigma-Aldrich) was added to a final concentration of 100 g/ml.
Isolation of neutrophils and their precursors from bone marrow and peripheral blood Isolation of neutrophil precursors and polymorphonuclear neutrophils (PMNs) was performed as described previously [35] . Briefly, bone marrow samples from healthy volunteers were separated by centrifugation on a two-layer Percoll™ (Amersham Biosciences, Buckinghamshire, UK) gradient, which resulted in separation of bone marrow cells into three bands containing neutrophil precursors of different maturity: myeloblasts (MB) and PM, MC ϩ MM, and band cells and segmented neutrophils (BCϩSC), respectively. PMNs from peripheral blood were isolated by centrifugation on Lymphoprep (Nygaard, Oslo, Norway). Non-neutrophil cells were removed from the cell populations by depletion using the magnetic cell sorter system (Miltenyi Biotec, Bergisch Gladbach, Germany).
Northern blot
RNA was extracted using Trizol LS reagent (Invitrogen Corp., Carlsbad, CA). An amount of 15 g total RNA was separated on a formaldehyde gel, followed by transfer to a GeneScreen plus membrane (NEN Life Science Products, Boston, MA). Equal loading, RNA quality, and transfer efficiency were checked by Radiant Red RNA stain (Bio-Rad Laboratories, Hercules, CA). A 730-base pair (bp) cDNA, corresponding to the amino-terminal half of BPI, was labeled with [ 32 P]deoxy-cytidine 5Ј-triphosphate using the Rediprime TM II kit (Amersham Biosciences). High-stringency hybridization was performed at 68°C with the ExpressHyb solution (BD Biosciences-Clontech, Palo Alto, CA). The membrane was washed with 2ϫ saline sodium citrate (SSC), 0.05% sodium dodecyl sulfate (SDS), 3 ϫ 10 min at room temperature, and 0.1ϫ SSC, 0.1% SDS, 2 ϫ 20 min at 50°C. Membranes were analyzed using a Molecular Imaging FX analyzer (Bio-Rad Laboratories).
Northern blotting of RNA from PMNs and neutrophil precursor populations and subsequent hybridization was performed as described previously [36] . The blot was hybridized to a 1695-bp BPI cDNA probe, and ␤-actin was used as equal loading control. cDNA probes for MPO and lactoferrin (LF) were as described [36] . The blot was developed and quantified using a PhosphorImager (FUJI X Bas 2000). The intensity of the signals from the probes was normalized to the intensity of the internal standard ␤-actin, as described [36] .
Biosynthetic labeling and immunoprecipitation
Biosynthetic radiolabeling and immunoprecipitation of newly synthesized proteins were performed with rabbit polyclonal BPI antibody [21] , as described elsewhere [37] . Immunoprecipitated material was analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) using 10 -20% Tris-glycine gels and fluorography.
Real-time reverse transcription-polymerase chain reaction (RT-PCR)
RT of 400 ng total RNA was performed using the Taqman kit (Applied Biosystems, Foster City, CA) and random hexamer primer. Real-time PCR was performed with Taqman probes in the 7000 Sequence Detection system (Applied Biosystems), according to the manufacturer's instructions. Specific primers and probes for human BPI, ␣-defensin 1-3, cathepsin G, proteinase 3, and LF were purchased from Applied Biosystems (Assay-by-Demand). Real-time RT-PCR of ␤2-microglobulin (Applied Biosystems) was used as an internal control. Data were collected and analyzed with the sequence detector, v.1.1, software (Applied Biosystems). Relative quantitative data were calculated based on the ⌬⌬C T method, where normalization is performed as follows:
; and relative quantification ϭ 2 Ϫ⌬⌬CT (reviewed in ref. [38] ).
Protein extracts and electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described previously [39] , with the modification that 0.6% Nonidet P-40 was included in the lysis buffer and that protease inhibitors, Complete (Roche Diagnostics GmbH, Mannheim, Germany), were used in all buffers. Probe was prepared by labeling DNA oligonucleotide probe with [␥-32 P]adenosine 5Ј-triphosphate, as described [25] . The oligonucleotide 5Ј-GGTTCCTTCCTCCTTTCCACATTCTACTGACT-3Ј, corresponding to -107/-76 bp, according to the numeration seen in Figure 4 and ref. [25] , was used as probe. Nuclear extract was incubated with the labeled DNA probe for 20 min at room temperature in binding buffer (HEPES, pH 7.9, 25 mM KCl, 1.25 mM MgCl 2 , 0.5 mM dithiothreitol, 0.5 mM EDTA, 1 mM ZnCl 2 , and 50% glycerol), supplemented with 0.3 g poly(dIdC)/15 l reaction mixture (Amersham Biosciences). The antibodies [C/EBP␣ (14aa)X, sc-61X, C/EBP␤ (1c-19)X, sc-150X, C/EBP␦ (m-17), sc-636, C/EBPε (c-22) sc-158, all from Santa Cruz Biotechnology, CA] were added together with labeled probe. The samples were separated on 6% polyacrylamide Tris-boric acid-EDTA gel and analyzed in a Molecular Imaging FX analyzer (Bio-Rad Laboratories).
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the ChIP assay kit (Upstate Biotechnology, Lake Placid, NY). Briefly, 1 million cells were cross-linked with 1% formaldehyde for 20 min, harvested, and sonicated 4 ϫ 40 s at 100% power using a UP 50H sonicator (Dr. Hielscher GmbH, Germany). After 30 min preclearing with salmon sperm DNA/protein A slurry, 6 g indicated antibody (see above) was added and incubated overnight at 4°C. The immunocomplexes were washed, after which the cross-linking was reversed by incubation at 65°C for 4 h in the presence of NaCl. After proteinase K treatment, the immunoprecipitated DNA was recovered with phenol/chloroform extraction and ethanol precipitation. The DNA was resuspended in 40 l water, of which 15 l was used as template in a 32-cycle PCR amplification, using forward primer 5Ј-CACACA-CATACACACACGCACG-3Ј and reverse primer 5Ј-AAGAGTCGGCTGGG-GAAATG-3Ј.
Western blotting
Western blotting analysis was performed, as described previously [40] . Briefly, 5 ϫ 10 6 cells were harvested, washed, and lysed. Extracted proteins were separated by SDS-PAGE and transferred to a Hybond-P membrane (Amersham Biosciences). Antibodies against the different C/EBPs (Santa Cruz Biotechnology) were used as primary antibodies and a peroxidase-conjugated swine anti-rabbit antiserum (Dako, Glostrup, Denmark) as secondary antibody. The electrochemiluminescence Western blotting detection system (Amersham Biosciences) was used for detection.
RESULTS
In vivo BPI mRNA expression profile during neutrophil differentiation
Three different granulocytic cell populations were purified from normal human bone marrow and depleted for non-neutrophilic cells as described [35, 36] . The neutrophil precursors were separated in populations highly enriched for MB ϩ PM, MC ϩ MM, and BC ϩ SC. Mature PMNs were extracted from peripheral blood. The different cell populations were investigated for BPI, LF, and MPO mRNA expression by Northern blotting technique. As shown in Figure 1 , BPI displayed a distinct mRNA expression profile, with a sharp peak in the MC ϩ MM population. This expression pattern is similar to that of the specific granule protein LF (Fig. 1 ) but quite distinct from the expression of MPO, which shows most pronounced expression in the MB ϩ PM population (Fig. 1) . Thus, the expression profile of BPI is different from that of other azurophil granule proteins such as MPO, which are mainly expressed during the MB and PM stage of maturation [36] . Rather, BPI shares the expression profile of mRNAs encoding LF and other specific granule proteins [36] . No BPI mRNA expression could be detected in peripheral neutrophils. [34] . NB4 cells undergo partial granulocytic maturation upon induction with ATRA. The maturation is only partial, as the cells undergo apparent phenotypic maturation but fail to express secondary granule protein genes [41] . In agreement with the in vivo expression profile of BPI, showing absence of BPI mRNA in PM (Fig. 1) , uninduced NB4 cells expressed no BPI. However, treatment of NB4 cells with 10 M ATRA for 24 h resulted in an up-regulation of BPI at the level of mRNA and protein, as judged by Northern blotting and biosynthetic labeling, respectively (Fig. 2) . For quantification of the increase in mRNA, real-time RT-PCR was performed. In addition, changes in mRNA of other azurophil and secondary granule proteins in response to ATRA were analyzed. It is interesting that an ϳ60-fold increase in BPI mRNA was specific for this transcript, inasmuch as mRNA expression for the azurophil granule proteins, cathepsin G and proteinase 3, was actually down-modulated after ATRA treatment ( Table 1) . Moreover, the expression of ␣-defensin 1-3 mRNA was almost unchanged, although a slight increase could be seen (Table 1) . No expression of the specific granule protein LF could be detected in accordance with previous data [41] . We conclude that treatment of NB4 cells with ATRA results in robust expression of BPI mRNA, and levels of other azurophil and specific granule protein mRNAs are decreased or unaffected.
ATRA induces BPI expression in NB4 cells
NB4 is a cell line derived from a patient with acute PM leukemia and harbors the t(15;17) chromosomal translocation
ATRA-induced expression of BPI mRNA is dependent on de novo protein synthesis
Real-time RT-PCR analysis revealed that BPI mRNA induction was detectable after 12 h (data not shown and Fig. 3) and that an ϳ60-fold increase was attained after 24 h of ATRA treatment (Table 1) . To investigate whether BPI mRNA induction was dependent on de novo protein synthesis, we inhibited protein synthesis with 100 g/ml cycloheximide. As shown in Figure 3 , cycloheximide completely abrogated ATRA-induced expression of BPI mRNA, indicating indirect effects of ATRA, possibly involving de novo synthesis of transcription factors.
ATRA-induced expression of BPI mRNA correlates to C/EBP␤ and C/EBP binding to the BPI promoter
The finding that ATRA-induced expression of BPI mRNA is dependent on de novo protein synthesis suggests that ATRA induces synthesis of a transcription factor that binds to the promoter of BPI. Different C/EBP family members have been shown to be ATRA-responsive in myeloid cells [32, 33] , and previous characterization of the BPI promoter has revealed C/EBP-binding sites in the proximal promoter [25] (Fig. 4) . Moreover, mutations of the C/EBP sites have been shown to reduce the promoter activity in HL-60 cells [25] . Therefore, we hypothesized that ATRA induces C/EBP binding to the proximal BPI promoter. To correlate activation of BPI expression by ATRA to C/EBP binding, we performed ChIP analysis and EMSA. Prior to ATRA induction of NB4 cells, no binding of C/EBP to the BPI promoter could be detected by ChIP (Fig. 5) . However, after 24 h of ATRA treatment, binding of C/EBP was clearly detected. The binding was specific for C/EBP␤ and C/EBPε, insofar as binding of C/EBP␣ and C/EBP␦ was not detected (Fig. 5) . Consequently, ChIP demonstrates that ATRA treatment induces C/EBP␤ and C/EBPε binding to the proximal promoter of BPI.
To gain further support for binding of C/EBP␤ and C/EBPε to the BPI promoter in response to ATRA, EMSA was performed. Nuclear extracts of ATRA-induced or uninduced NB4 cells were mixed with an oligonucleotide corresponding to -107 to -76 bp in the promoter, containing a putative C/EBP site (Fig. 4) . We have, in previous analyses, shown that this upstream C/EBP site is the most important for BPI expression [25] . Therefore, an EMSA probe containing this C/EBP site was used in our assay (Fig. 4) . Indeed, a shift appeared after induction with ATRA, which could not be obtained with uninduced nuclear extract and consequently, was specific for ATRA-induced cells (Fig. 6) . Although addition of antibodies against different C/EBP family members did not result in any obvious supershift, the specific shift disappeared after addition of antibodies against C/EBP␤, C/EBP␦, and C/EBPε but not after addition of antibodies against C/EBP␣. The elimination of the shift is likely to have been the result of antibody interaction with the DNA-binding protein, disturbing its DNA-binding capacity, indicating binding of C/EBP␤, C/EBP␦, and C/EBPε to the oligonucleotide. As the induced shift remained unaffected after incubation with antibody against C/EBP␣, the data suggest that C/EBP␣ is not bound to this part of the BPI promoter after induction with ATRA. We conclude from the ChIP analysis and EMSA that ATRA-induced expression of BPI in NB4 cells correlates to the appearance of C/EBP␤ and C/EBPε bound to the proximal promoter. Although EMSA also indicated binding of C/EBP␦, this observation was not supported by ChIP analysis.
C/EBP␤ and C/EBP expression is up-regulated by ATRA stimulation of NB4 cells
Results described above indicate that ATRA-induced expression of BPI involves binding of C/EBP␤ and C/EBPε to the promoter of BPI (Figs. 5 and 6) . Given that the effect of ATRA on BPI expression is dependent on de novo protein synthesis (Fig. 3) , we asked whether ATRA increases the protein levels of C/EBP␤ and C/EBPε in NB4 cells. As shown in Figure 7 , this is indeed the case; C/EBP␤ was not expressed in uninduced cells, but ATRA treatment for 24 h strongly induced C/EBP␤ protein (Fig. 7) . In the case of C/EBPε, uninduced NB4 cells also expressed significant levels of protein, but ATRA treatment further increased C/EBPε protein, especially the p27 isoform and more moderately, the p30 isoform (Fig. 7) . By contrast, the protein levels of C/EBP␣ and C/EBP␦ were unaffected or decreased in response to ATRA (Fig. 7) . We conclude that ATRA increases the protein levels of C/EBP␤ and C/EBPε.
DISCUSSION
The present study shows that BPI is expressed in the MC and MM cell population, and most azurophil granule proteins are NB4 cells were incubated with or without ATRA (10 M) for 24 h. Total RNA was extracted, and levels of mRNA were determined with real time RT-PCR. The given values are fold change of mRNA levels in cells treated with ATRA compared with untreated cells. Level of ␤2-microglobulin mRNA was used as an internal control, and the relative mRNA expression was calculated as follows: ⌬C T ϭ C T (sample) -C T (␤2-microglobulin); ⌬⌬C T ϭ ⌬C T (induced) -⌬C T (uninduced); relative quantification ϭ 2 -⌬⌬CT (reviewed in ref. [33] ). Mean values, n ϭ 2, are presented, and each experiment is performed in triplicate. Fig. 3 . ATRA-induced expression of BPI mRNA in NB4 cells is dependent on de novo protein synthesis. NB4 cells were treated with 10 M ATRA for up to 24 h. Cycloheximide (100 g/ml) was added to parallel incubations to investigate dependence on protein synthesis. Total RNA was extracted, and BPI mRNA expression was determined with real-time-RT-PCR. The figure shows levels of BPI mRNA normalized to the level in uninduced control cells, mean values Ϯ ranges (nϭ2).
expressed during the PM stage of maturation [18, 19] . Thus, BPI displays an expression pattern more similar to specific granule proteins than other azurophil granule proteins. BPI shares this characteristic with defensin, for which the levels of mRNA and protein during myeloid maturation reach their highest level after the peak of expression of most other azurophil proteins [36] . Moreover, BPI and defensins are the only azurophil granule proteins included in SGD [28] , indicating transcriptional control mechanisms in common with those of genes encoding specific granule proteins.
The present data demonstrate that ATRA strongly induces transcription of BPI in human PM NB4 cells. The positive response of BPI mRNA to ATRA was not shared by proteinase 3 and cathepsin G, the expression of which was rather downregulated. The effect of ATRA on expression of BPI involves de novo protein synthesis, as inhibition of protein synthesis completely abrogated an ATRA-induced increase of BPI mRNA. The fairly slow induction of BPI mRNA in response to ATRA is compatible with a requirement of de novo protein synthesis, which is also in agreement with previous failure to reveal retinoic acid response elements (RAREs) in the proximal promoter of BPI [25] . Given that induction of BPI expression by ATRA in NB4 cells correlated to increased levels of C/EBPε and C/EBP␤ protein and also to direct binding of C/EBPε and C/EBP␤ to the BPI promoter, as demonstrated by ChIP and EMSA, our data strongly propose that C/EBPε and C/EBP␤ are mediators of the effects of ATRA on the BPI promoter. C/EBPε was, in contrary to C/EBP␤, also expressed in uninduced NB4 cells. However, no C/EBPε binding to the BPI promoter could be detected in uninduced NB4 cells. Whether, this is a result of required heterodimer formation with C/EBP␤ or post-transcriptional modifications of C/EBPε, such as phosphorylation [42] , remains to be elucidated.
C/EBPε is involved in transcriptional regulation of genes encoding specific granule proteins such as LF and collagenase [43, 44] , and C/EBPε is essential for late granulocytic differentiation [45] . Our present results are consistent with previous reports that C/EBPε is up-regulated in NB4 after treatment with ATRA via RAREs in the C/EBPε promoter [32, 46] and that C/EBP␤ expression and DNA binding are induced rapidly by ATRA via a PM leukemia-retinoic acid receptor ␣-dependent pathway in NB4 cells [33] .
Evidence for the critical role of C/EBPε in the regulation of BPI is provided by the previous observation that BPI expression is absent in SGD patients with homozygous mutation of C/EBPε [28, 29] . Besides BPI, defensins are the only azurophil granule components that are absent in SGD patients [47] . It is interesting that C/EBPε binds to the promoter of neutrophil defensins after ATRA stimulation of NB4 cells [48] . It is therefore likely that defensins and BPI share common regulatory mechanisms, including C/EBPε. In NB4 cells, however, ATRA caused only a modest increase in the amount of ␣-defensin mRNA, and the increase in BPI mRNA was almost 60-fold, suggesting that robust expression of ␣-defensins needs additional transcriptional activators or release of transcriptional repression.
Our results demonstrate that besides C/EBPε, C/EBP␤ also contributes to the C/EBP DNA-binding complex. C/EBP␤ is important for monocytic maturation but is also involved in neutrophil [33, 49] and eosinophil [50] differentiation. Moreover, expression of C/EBP␤ and C/EBPε is up-regulated during neutrophil maturation in vivo [35] . Given that BPI is present primarily in neutrophils [20, 21] but also in eosinophils [22] and on the surface of monocytes [23] , C/EBP␤ may be a common regulator of BPI in all three cell types.
Results of the EMSA suggest that C/EBP␦ also participates in ATRA-induced BPI regulation. C/EBP␦ and C/EBPε have been shown to activate transcription of genes encoding specific granule proteins [42, 48] . Binding of C/EBP␦ to the BPI promoter was not, however, confirmed by the ChIP analysis. Therefore, additional experiments are required to clearly demonstrate a role for C/EBP␦ in BPI expression. Fig. 4 . Sequence of the EMSA probe with C/EBP site in relation to partial sequence of the BPI promoter (adopted from ref. [25] ). Numeration from the ATG translation start site in bold. Transcription start sites are indicated with arrows; C/EBP-and PU.1-binding sites are underlined [25] . Fig. 5 . ChIP analysis to calculate the degree of binding of C/EBP␤ and C/EBPε to the BPI promoter. NB4 cells incubated for 24 h with or without 10 M ATRA were used in ChIP analyses. Specific antibodies for the various C/EBP family members were used in the immunoprecipitation, and antibodies against cyclin D1 were used as a negative control. The last lane is a negative control containing no template. Typical result is shown.
In our previous characterization of the proximal promoter of BPI, we identified a potential C/EBP-binding site (-100), partly overlapping a PU.1 site, which is functionally important for constitutive expression of BPI in HL-60 cells [25] . However, in contrast to HL-60 cells, PU.1 does not bind to this site in uninduced NB4 cells [25] . Taken together, data indicate that PU.1 and C/EBP can bind to sites close to each other and that both factors affect promoter activity in a positive way. In HL-60 cells, a transiently transfected BPI promoter driving the luciferase reporter gene clearly lost transcriptional activity after mutation of the C/EBP/PU.1 site [25] . Recent investigations about the transcriptional regulation of BPI in epithelial cells give further support for a prominent role of C/EBP [51] . Unfortunately, it was not possible to evaluate the effect of ATRA on promoter-reporter constructs in NB4 cells, as ATRA rapidly down-modulated all transiently transfected luciferase reporter cells, including positive and internal controls, with strong viral promoters. The reason for this is unclear, but it made it impossible to use ATRA in reporter experiments.
In conclusion, the present data demonstrate that BPI mRNA is expressed in vivo in a MC and MM cell population. Moreover, ATRA-induced BPI expression involves induction of C/EBP␤ and C/EBPε, and binding of these transcription factors to the promoter correlates to BPI expression. Transcriptional activation dependent on C/EBP␤ and C/EBPε may be a feature of the transcriptional control of BPI, which is related to the transcriptional control of specific granule proteins and distinct from that of most other azurophil granule proteins. (Fig. 4 ), was incubated with nuclear extract from NB4 cells treated for 24 h with or without 10 M ATRA. Arrows indicate the shifts, as well as free probe. Specific antibodies for C/EBP members were added to the reaction mixtures, as indicated.
Fig. 7.
Western blot of C/EBP protein in ATRA-induced NB4 cells, which were incubated for 24 h with or without 10 M ATRA and were lysed and subjected to SDS-PAGE and immunoblot analysis using antibodies against different C/EBP family members. Immunoblotting with antibody against actin was used as control of equal loading. Positions of C/EBP proteins and C/EBPε protein isoforms are indicated with arrows.
